Early UVFP Management Based on Neurological Evidences (UVFP = Unilateral Vocal Fold Paralysis)

NCT ID: NCT03906877

Last Updated: 2023-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-15

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to understand how early intervention could impact reinnervation of the recurrent laryngeal nerve (which innervates the vocal cord), recovery of mobility of the paralyzed vocal cord and / or vocal recovery in the case of unilateral vocal fold paralysis. To achieve this goal we must therefore carry out a complete outcomes assessment of different intervention methods (voice therapy and injection laryngoplasty), which are offered to UVFP (unilateral vocal fold paralysis) patients in the early stage (\< 3 months). Their respective impacts on the central and peripheral nervous system and on the voice quality will be assessed, taking into account factors related to the severity of the paralysis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Unilateral Vocal Cord Paralysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Injection laryngoplasty group (IL)

The patients in the first group will receive an IL of hyaluronic acid in the paralyzed vocal fold within a maximum of three months after the onset of symptoms. The Ear-Noise-Throat (ENT) physician will perform the injection in office, under topical anaesthesia.

Group Type EXPERIMENTAL

Acid hyaluronic injection laryngoplasty

Intervention Type PROCEDURE

Hyaluronic acid is injected into the paralyzed vocal fold

Sham of voice therapy

Intervention Type OTHER

15 sessions of thirty minutes of voice therapy, twice a week, and home practice.

This voice management will not be specific to UVFP but may allow patients to improve their vocal gesture.

Voice therapy group (VT)

Patients from the second group will be involved in 15 sessions of thirty minutes of voice therapy, twice a week, and will have to do home practice. Patients will have to record these training sessions. Initiation of this intervention should also take place within the first three months after the onset of symptoms. They will also receive an injection of physiological saline under the skin of the neck (sham of injection).

Group Type EXPERIMENTAL

Voice therapy

Intervention Type BEHAVIORAL

15 sessions of thirty minutes of voice therapy, twice a week, and home practice.

This voice management will be specific to unilateral vocal fold paralysis and will focus on three objectives: reinforcement of the vocal muscle, glottal closure and glottal opening. These three objectives will be worked through different vocal exercises (on voiced phonemes) and breathing exercises

Sham of injection

Intervention Type OTHER

Injection of physiological saline under the skin of the neck (sham of injection).

Sham group

The patients of the third group will be treated following the traditional wait-and-see policy. They will receive an injection of physiological saline under the skin of the neck and will be seen during 15 sessions of 30 minutes, twice a week. Therefore, this will be a sham procedure for both IL and VT.

Group Type SHAM_COMPARATOR

Sham of injection

Intervention Type OTHER

Injection of physiological saline under the skin of the neck (sham of injection).

Sham of voice therapy

Intervention Type OTHER

15 sessions of thirty minutes of voice therapy, twice a week, and home practice.

This voice management will not be specific to UVFP but may allow patients to improve their vocal gesture.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acid hyaluronic injection laryngoplasty

Hyaluronic acid is injected into the paralyzed vocal fold

Intervention Type PROCEDURE

Voice therapy

15 sessions of thirty minutes of voice therapy, twice a week, and home practice.

This voice management will be specific to unilateral vocal fold paralysis and will focus on three objectives: reinforcement of the vocal muscle, glottal closure and glottal opening. These three objectives will be worked through different vocal exercises (on voiced phonemes) and breathing exercises

Intervention Type BEHAVIORAL

Sham of injection

Injection of physiological saline under the skin of the neck (sham of injection).

Intervention Type OTHER

Sham of voice therapy

15 sessions of thirty minutes of voice therapy, twice a week, and home practice.

This voice management will not be specific to UVFP but may allow patients to improve their vocal gesture.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Unilateral paralysis in abduction of the vocal cords may be included in the study.

Exclusion Criteria

* Wear a pacemaker or other implanted devices (prostheses ...).
* Wear metal clips, metal in the head, or an adjustable brain drain.
* Wear non-removable dental appliances (except fillings).
* Wear cardiac valve prostheses.
* Have worked the metals.
* Have a tattoo containing metal particles.
* Have implanted jewelry (e.g., piercing).
* Being prone to epileptic seizures.
* Take medications that alter cortical excitability.
* Have had a brain surgery.
* Suffer from intracranial hypertension.
* Be pregnant or breastfeeding recently.
* Present allergies that are incompatible with the experimental protocol.
* Have an abnormal hearing loss in view of their age, identified with tonal and / or vocal audiometry.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gauthier Desuter

Role: PRINCIPAL_INVESTIGATOR

SSS/MEDE and SSS/IONS/NEUR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cliniques Universitaires St Luc

Brussels, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018/03OCT/365

Identifier Type: -

Identifier Source: org_study_id